Discover
DBVT
DBV Technologies S.A.
15.73
1 x 16.25
1 x 15.96
bid
ask
-
0.67
4.09%
1 @ 04:00 PM
15.64 -0.09 (0.57%)
| Ytd | -17.94% | |
| 1y | 49.95% |
15.26
day range
16.58
8.51
52 week range
26.18
| Open | 16.40 | Prev Close | 16.40 | Low | 15.26 | High | 16.58 | Mkt Cap | 931.01M |
| Vol | 265.65K | Avg Vol | 255.65K | EPS | -4.50 | P/E | N/A | Forward P/E | -37.06 |
| Beta | -0.22 | Short Ratio | 7.31 | Inst. Own | 37.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 18.24 | 200-d Avg | 17.87 | 1yr Est | 40.52 |
DBVT News
benzinga.com
Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55
Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperf
seekingalpha.com
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Pat
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Pat
globenewswire.com
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 thr
Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Pe
benzinga.com
DBV Technologies To Present New Data From VITESSE Study And Preview Recently Initiated THRIVE Study
In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy
benzinga.com
DBV Technologies Starts Infant Study of Peanut Allergy Patch
DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first